Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, o...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The lancet oncology Ročník 19; číslo 3; s. 416 - 426
Hlavní autori: D'Angelo, Sandra P, Mahoney, Michelle R, Van Tine, Brian A, Atkins, James, Milhem, Mohammed M, Jahagirdar, Balkrishna N, Antonescu, Cristina R, Horvath, Elise, Tap, William D, Schwartz, Gary K, Streicher, Howard
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 01.03.2018
Elsevier Limited
Predmet:
Adult
Adverse events
Aged
Aged, 80 and over
Alanine
Alanine transaminase
Anemia
Anorexia
Antibodies
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Aspartate aminotransferase
Biomarkers
Bone cancer
Cancer therapies
Cell number
Chemotherapy
Clinical trials
Creatinine
CTLA-4 protein
Dehydration
Diarrhea
Disease
FDA approval
Female
Fever
Hematology, Oncology, and Palliative Medicine
Humans
Hypotension
Immunotherapy
Intravenous administration
Ipilimumab - adverse effects
Ipilimumab - therapeutic use
Ligands
Liposarcoma
Lung cancer
Lymphocytes
Male
Medical prognosis
Melanoma
Metastases
Metastasis
Middle Aged
Monoclonal antibodies
Neoplasia
Nivolumab - adverse effects
Nivolumab - therapeutic use
Oncology
Pain
Patients
PD-1 protein
Pleural effusion
Pruritus
Respiratory failure
Sarcoma
Sarcoma - drug therapy
Sarcoma - immunology
Sarcoma - mortality
Sarcoma - secondary
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - immunology
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - pathology
Soft tissue sarcoma
Solid tumors
Targeted cancer therapy
Time Factors
Treatment Outcome
Tumors
United States
Urinary tract
Young Adult
United States
United States > US
ISSN:1470-2045, 1474-5488, 1474-5488
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. We did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0–1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797. Between Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1–16] of 38 patients) in the nivolumab group and six (16% [7–30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths. Nivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted. Alliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
AbstractList Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma.BACKGROUNDPatients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma.We did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0-1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797.METHODSWe did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0-1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797.Between Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1-16] of 38 patients) in the nivolumab group and six (16% [7-30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths.FINDINGSBetween Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1-16] of 38 patients) in the nivolumab group and six (16% [7-30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths.Nivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted.INTERPRETATIONNivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted.Alliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.FUNDINGAlliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. We did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0-1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797. Between Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1-16] of 38 patients) in the nivolumab group and six (16% [7-30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths. Nivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted. Alliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
SummaryBackgroundPatients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. MethodsWe did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0–1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797. FindingsBetween Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1–16] of 38 patients) in the nivolumab group and six (16% [7–30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths. InterpretationNivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted. FundingAlliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
Sarcomas are rare, heterogeneous malignant tumours of mesenchymal origin characterised into more than 100 distinct subtypes, accounting for 1% of malignancies in adults.1 For newly diagnosed patients with metastatic sarcoma who are chemotherapy naive, the efficacy of approved treatments, doxorubicin alone or gemcitabine plus docetaxel, is similar,2 with approximately 18% of patients achieving objective responses with these regimens, with progression-free survival of approximately 5 months and overall survival of 16 months.
Summary Background Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We investigated the activity and safety of nivolumab alone or in combination with ipilimumab in patients with locally advanced, unresectable, or metastatic sarcoma. Methods We did a multicentre, open-label, non-comparative, randomised, phase 2 study that enrolled patients aged 18 years or older and had central pathology confirmation of sarcoma with at least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, evidence of metastatic, locally advanced or unresectable disease, an ECOG performance status of 0–1, and received at least one previous line of systemic therapy. Patients were assigned to treatment in an unblinded manner, as this trial was conducted as two independent, non-comparative phase 2 trials. Enrolled patients were assigned (1:1) via a dynamic allocation algorithm to intravenous nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses. Thereafter, all patients received nivolumab monotherapy (3 mg/kg) every 2 weeks for up to 2 years. The primary endpoint was the proportion of patients with locally advanced, unresectable or metastatic soft tissue sarcoma achieving a confirmed objective response. Analysis was per protocol. This study is ongoing although enrolment is closed. It is registered with ClinicalTrials.gov, number NCT02500797. Findings Between Aug 13, 2015, and March 17, 2016, 96 patients from 15 sites in the USA underwent central pathology review for eligibility and 85 eligible patients, including planned over-enrolment, were allocated to receive either nivolumab monotherapy (43 patients) or nivolumab plus ipilimumab (42 patients). The primary endpoint analysis was done according to protocol specifications in the first 76 eligible patients (38 patients per group). The number of confirmed responses was two (5% [92% CI 1–16] of 38 patients) in the nivolumab group and six (16% [7–30] of 38 patients) in the nivolumab plus ipilimumab group. The most common grade 3 or worse adverse events were anaemia (four [10%] patients), decreased lymphocyte count (three [7%]), and dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction (two [5%] patients each) among the 42 patients in the nivolumab group and anaemia (eight [19%] patients), hypotension (four [10%] patients), and pain and urinary tract infection (three [7%] patients each) among the 42 patients in the nivolumab plus ipilimumab group. Serious treatment-related adverse events occurred in eight (19%) of 42 patients receiving monotherapy and 11 (26%) of 42 patients receiving combination therapy, and included anaemia, anorexia, dehydration, decreased platelet count, diarrhoea, fatigue, fever, increased creatinine, increased alanine aminotransferase, increased aspartate aminotransferase, hyponatraemia, pain, pleural effusion, and pruritus. There were no treatment-related deaths. Interpretation Nivolumab alone does not warrant further study in an unselected sarcoma population given the limited efficacy. Nivolumab combined with ipilimumab demonstrated promising efficacy in certain sarcoma subtypes, with a manageable safety profile comparable to current available treatment options. The combination therapy met its predefined primary study endpoint; further evaluation of nivolumab plus ipilimumab in a randomised study is warranted. Funding Alliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
Author Antonescu, Cristina R
Mahoney, Michelle R
Schwartz, Gary K
Horvath, Elise
Milhem, Mohammed M
Streicher, Howard
D'Angelo, Sandra P
Van Tine, Brian A
Atkins, James
Jahagirdar, Balkrishna N
Tap, William D
Author_xml – sequence: 1
  givenname: Sandra P
  surname: D'Angelo
  fullname: D'Angelo, Sandra P
  email: dangelos@mskcc.org
  organization: Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 2
  givenname: Michelle R
  surname: Mahoney
  fullname: Mahoney, Michelle R
  organization: Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
– sequence: 3
  givenname: Brian A
  surname: Van Tine
  fullname: Van Tine, Brian A
  organization: Washington University in Saint Louis School of Medicine, St Louis, MO, USA
– sequence: 4
  givenname: James
  surname: Atkins
  fullname: Atkins, James
  organization: Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, NC, USA
– sequence: 5
  givenname: Mohammed M
  surname: Milhem
  fullname: Milhem, Mohammed M
  organization: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, IA, USA
– sequence: 6
  givenname: Balkrishna N
  surname: Jahagirdar
  fullname: Jahagirdar, Balkrishna N
  organization: Regions Hospital Cancer Care Center, Saint Paul, MO, USA
– sequence: 7
  givenname: Cristina R
  surname: Antonescu
  fullname: Antonescu, Cristina R
  organization: Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 8
  givenname: Elise
  surname: Horvath
  fullname: Horvath, Elise
  organization: Astellas, Northbrook, IL, USA
– sequence: 9
  givenname: William D
  surname: Tap
  fullname: Tap, William D
  organization: Memorial Sloan Kettering Cancer Center, New York, NY, USA
– sequence: 10
  givenname: Gary K
  surname: Schwartz
  fullname: Schwartz, Gary K
  organization: Columbia University School of Medicine/Herbert Irving Cancer Center, New York, NY, USA
– sequence: 11
  givenname: Howard
  surname: Streicher
  fullname: Streicher, Howard
  organization: National Cancer Institute, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29370992$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1u1DAUhSNURH_gEUCW2EylCVwnceIUARpV_EkVLIC15Tg3qosTB9uZqg_C--JkShcjQVldy_nO8c05x8nBYAdMkqcUXlCg5cuvtKggzaBgK8pPcwAoU_4gOYrXRcoKzg-W8w45TI69vwKgFQX2KDnM6ryCus6Okl-f9daaqZcNudbhkli3TDsFokdtdL98Cg5l6HEIpItAj0H6IINWxEunbC_JamOMloNCsoGaFkBPz0i4tsSOOKRGNmjWJP5AGuFRuijd4po4ObS21x7bNRkvpUeSxZe0NP5x8rCLA5_czpPk-_t3384_phdfPnw631ykilVVSAtgtOHQ1pjTHNqOdkopWnac8goUNBnmyBBaXjLFZJPlinXAGs7KgqsYQX6SrHa-o7M_J_RBxHUUGiMHtJMXNGYUw2ZQRvT5HnplJzfE7UTGyjLLy5rDPymgWc7m1SL17Jaamh5bMTrdS3cj_tQSAbYDlLPeO-zuEApirl8s9Yu5W0G5WOoXPOpe7emUnouyQ3BSm3vVb3dqjJFvNTrhlcZYaqsdqiBaq-91eLPnoIwetJLmB96gv8uCCp8J2JnMHpQvDrPB678b_McCvwF9m-8S
CitedBy_id crossref_primary_10_1007_s00292_019_0628_x
crossref_primary_10_1016_j_hoc_2025_04_010
crossref_primary_10_1038_s41416_019_0616_1
crossref_primary_10_1002_hon_2743
crossref_primary_10_1038_s41698_025_00878_w
crossref_primary_10_3389_fbioe_2022_953555
crossref_primary_10_1158_0008_5472_CAN_19_1269
crossref_primary_10_3389_fonc_2023_1198292
crossref_primary_10_1136_jitc_2025_012357
crossref_primary_10_1080_14656566_2021_1936499
crossref_primary_10_2217_imt_2022_0157
crossref_primary_10_3389_fimmu_2025_1605958
crossref_primary_10_3390_dermatopathology8010008
crossref_primary_10_1016_j_heliyon_2023_e15527
crossref_primary_10_3389_fphar_2019_01671
crossref_primary_10_1177_25151355231192043
crossref_primary_10_1016_j_xcrm_2025_101977
crossref_primary_10_3389_fonc_2021_624780
crossref_primary_10_3389_fonc_2022_755053
crossref_primary_10_1007_s11864_022_00951_7
crossref_primary_10_1002_ijc_31717
crossref_primary_10_1080_14737140_2020_1760848
crossref_primary_10_3389_fonc_2021_725484
crossref_primary_10_1002_pbc_29442
crossref_primary_10_1038_s41379_019_0312_y
crossref_primary_10_3390_cancers16050938
crossref_primary_10_1080_14728214_2019_1591367
crossref_primary_10_1111_1759_7714_13541
crossref_primary_10_3390_cancers15030682
crossref_primary_10_3389_fonc_2021_684733
crossref_primary_10_1186_s12967_022_03589_z
crossref_primary_10_1002_cncr_35628
crossref_primary_10_1158_1078_0432_CCR_24_1854
crossref_primary_10_1136_gutjnl_2018_316948
crossref_primary_10_1002_cam4_70750
crossref_primary_10_3390_cancers13030498
crossref_primary_10_3389_fimmu_2022_893177
crossref_primary_10_3389_fonc_2022_849793
crossref_primary_10_1158_2326_6066_CIR_19_0072
crossref_primary_10_5306_wjco_v11_i4_180
crossref_primary_10_3389_fonc_2020_581107
crossref_primary_10_1093_cei_uxac068
crossref_primary_10_2340_1651_226X_2025_43135
crossref_primary_10_3390_biomedicines10030650
crossref_primary_10_1038_s41467_022_30874_8
crossref_primary_10_1002_pbc_29787
crossref_primary_10_1158_1078_0432_CCR_19_1824
crossref_primary_10_3390_cancers13030363
crossref_primary_10_1007_s00432_024_05661_1
crossref_primary_10_1007_s11864_020_0705_7
crossref_primary_10_3390_cancers15030588
crossref_primary_10_1016_j_critrevonc_2022_103700
crossref_primary_10_1002_iub_2655
crossref_primary_10_1186_s12885_020_07021_x
crossref_primary_10_1002_cam4_6303
crossref_primary_10_3389_fimmu_2021_775761
crossref_primary_10_2174_0118715206369319250402150638
crossref_primary_10_1097_MD_0000000000041165
crossref_primary_10_3390_cancers11010001
crossref_primary_10_3389_fped_2025_1638152
crossref_primary_10_1007_s11864_023_01139_3
crossref_primary_10_1007_s11864_025_01349_x
crossref_primary_10_3390_cancers17183068
crossref_primary_10_1038_s41388_021_02170_0
crossref_primary_10_1158_1078_0432_CCR_21_2105
crossref_primary_10_1016_j_ebiom_2024_105220
crossref_primary_10_2174_1381612828666220921151750
crossref_primary_10_1186_s12885_019_5785_z
crossref_primary_10_3390_cancers17050889
crossref_primary_10_2478_fco_2021_0005
crossref_primary_10_1038_s41586_019_1906_8
crossref_primary_10_1111_ijd_14705
crossref_primary_10_1136_jitc_2021_002990
crossref_primary_10_1080_2162402X_2025_2534912
crossref_primary_10_3390_ijms19123784
crossref_primary_10_1007_s00432_022_04000_6
crossref_primary_10_1038_s41422_020_0277_x
crossref_primary_10_1016_j_critrevonc_2019_04_008
crossref_primary_10_1111_imr_12772
crossref_primary_10_1080_14656566_2024_2427333
crossref_primary_10_1177_1078155220965677
crossref_primary_10_1016_j_modpat_2023_100165
crossref_primary_10_2217_fon_2022_0392
crossref_primary_10_3390_cancers12082251
crossref_primary_10_1136_jitc_2020_001355
crossref_primary_10_1158_1078_0432_CCR_22_1471
crossref_primary_10_1111_imr_12766
crossref_primary_10_1016_j_intimp_2018_08_014
crossref_primary_10_1016_j_critrevonc_2019_04_010
crossref_primary_10_3390_jpm13040668
crossref_primary_10_1186_s40425_019_0759_x
crossref_primary_10_1158_1078_0432_CCR_24_2503
crossref_primary_10_3390_ijms241512520
crossref_primary_10_1136_jitc_2020_001580
crossref_primary_10_1158_1078_0432_CCR_24_1782
crossref_primary_10_1007_s00261_019_01935_2
crossref_primary_10_1515_med_2023_0886
crossref_primary_10_3390_cancers12113153
crossref_primary_10_3390_cancers13215521
crossref_primary_10_3892_mco_2025_2889
crossref_primary_10_1016_j_jvir_2021_08_017
crossref_primary_10_3390_cancers15072099
crossref_primary_10_3390_cancers12113392
crossref_primary_10_1158_1078_0432_CCR_24_2519
crossref_primary_10_3390_cancers13020360
crossref_primary_10_1002_cnr2_1327
crossref_primary_10_3390_biomedicines10030573
crossref_primary_10_1038_s43018_024_00726_z
crossref_primary_10_3390_cells12172204
crossref_primary_10_1158_1078_0432_CCR_21_3445
crossref_primary_10_3390_cancers13051086
crossref_primary_10_1097_CCO_0000000000001050
crossref_primary_10_1016_j_soi_2024_100091
crossref_primary_10_1177_20363613241290788
crossref_primary_10_1158_1078_0432_CCR_20_0357
crossref_primary_10_3390_cancers14143414
crossref_primary_10_1080_2162402X_2019_1629779
crossref_primary_10_3390_biomedicines13030664
crossref_primary_10_1097_CCO_0000000000000843
crossref_primary_10_1007_s00262_025_04123_y
crossref_primary_10_1111_os_13620
crossref_primary_10_3390_cancers14071831
crossref_primary_10_1007_s12094_021_02723_5
crossref_primary_10_1158_1078_0432_CCR_22_0240
crossref_primary_10_3390_cancers14235753
crossref_primary_10_1038_s41416_021_01456_0
crossref_primary_10_3390_cimb46110751
crossref_primary_10_1016_j_ctrv_2020_102115
crossref_primary_10_3390_ijms222111564
crossref_primary_10_1186_s12885_021_08165_0
crossref_primary_10_1016_j_suc_2020_02_015
crossref_primary_10_1200_EDBK_432234
crossref_primary_10_1186_s12885_020_07456_2
crossref_primary_10_3390_cancers16091763
crossref_primary_10_3390_ijms24119571
crossref_primary_10_1016_j_ccell_2023_12_013
crossref_primary_10_1080_2162402X_2021_1896658
crossref_primary_10_1155_2020_5059079
crossref_primary_10_1200_JCO_18_02374
crossref_primary_10_1093_jjco_hyab005
crossref_primary_10_3390_life15040673
crossref_primary_10_1002_cncr_34370
crossref_primary_10_14348_molcells_2023_0079
crossref_primary_10_1136_jitc_2025_012053
crossref_primary_10_3389_fimmu_2021_720748
crossref_primary_10_1080_07357907_2020_1714053
crossref_primary_10_3390_ijms23073817
crossref_primary_10_7759_cureus_72119
crossref_primary_10_1186_s12967_022_03679_y
crossref_primary_10_3390_cancers17050821
crossref_primary_10_1002_cac2_12373
crossref_primary_10_1080_14737140_2021_1880327
crossref_primary_10_1159_000507334
crossref_primary_10_2217_fon_2020_0967
crossref_primary_10_3390_cancers15174339
crossref_primary_10_7759_cureus_12262
crossref_primary_10_1080_1120009X_2021_1913703
crossref_primary_10_2147_CMAR_S337253
crossref_primary_10_1002_jvc2_333
crossref_primary_10_1097_PAS_0000000000001254
crossref_primary_10_1016_j_cbi_2024_110931
crossref_primary_10_1002_pbc_30491
crossref_primary_10_70352_scrj_cr_24_0049
crossref_primary_10_1080_1750743X_2025_2558376
crossref_primary_10_1016_j_ijgc_2025_101992
crossref_primary_10_1038_s41467_020_14646_w
crossref_primary_10_1186_s12967_020_02588_2
crossref_primary_10_3389_fonc_2019_00922
crossref_primary_10_3390_cancers14194578
crossref_primary_10_1016_j_compbiomed_2025_110144
crossref_primary_10_1080_14740338_2020_1811226
crossref_primary_10_3390_cancers15143705
crossref_primary_10_1016_j_semradonc_2023_12_002
crossref_primary_10_1016_j_semradonc_2023_12_001
crossref_primary_10_1038_s41467_022_30453_x
crossref_primary_10_1016_j_cpccr_2022_100202
crossref_primary_10_1016_j_semradonc_2023_12_005
crossref_primary_10_1016_S1470_2045_23_00282_6
crossref_primary_10_1136_jitc_2021_002345
crossref_primary_10_1038_s41598_025_95173_w
crossref_primary_10_1007_s00381_020_04687_3
crossref_primary_10_1177_17588359231198943
crossref_primary_10_5604_01_3001_0054_6746
crossref_primary_10_1158_2159_8290_CD_18_0618
crossref_primary_10_3389_fonc_2021_562315
crossref_primary_10_2217_imt_2023_0110
crossref_primary_10_1016_j_ejca_2018_10_011
crossref_primary_10_1038_s41467_023_39486_2
crossref_primary_10_2217_imt_2021_0066
crossref_primary_10_3892_mco_2025_2826
crossref_primary_10_1186_s40364_023_00552_y
crossref_primary_10_2217_imt_2023_0001
crossref_primary_10_3389_fimmu_2020_00274
crossref_primary_10_3389_fimmu_2024_1330868
crossref_primary_10_1200_EDBK_350541
crossref_primary_10_3389_fphar_2023_1093194
crossref_primary_10_3390_cancers14092320
crossref_primary_10_3390_jcm10153230
crossref_primary_10_3389_fmed_2022_1058863
crossref_primary_10_3389_fphar_2020_00040
crossref_primary_10_2217_imt_2021_0297
crossref_primary_10_1007_s00392_023_02251_y
crossref_primary_10_1007_s11096_023_01678_7
crossref_primary_10_12688_f1000research_15953_1
crossref_primary_10_1158_1078_0432_CCR_21_4239
crossref_primary_10_1016_j_jmb_2018_05_030
crossref_primary_10_1158_0008_5472_CAN_24_3281
crossref_primary_10_3390_cells10051170
crossref_primary_10_1038_s41598_024_61860_3
crossref_primary_10_12688_f1000research_15868_1
crossref_primary_10_4081_ejh_2021_3203
crossref_primary_10_3389_fonc_2023_1149106
crossref_primary_10_1016_j_critrevonc_2024_104575
crossref_primary_10_1186_s12885_021_08069_z
crossref_primary_10_1186_s12943_023_01720_2
crossref_primary_10_1080_13543784_2019_1555236
crossref_primary_10_1016_j_eclinm_2024_102991
crossref_primary_10_3389_fonc_2022_990670
crossref_primary_10_3390_vetsci11080362
crossref_primary_10_3390_cancers15010272
crossref_primary_10_3390_cancers17010010
crossref_primary_10_1016_j_ejso_2022_06_008
crossref_primary_10_1158_1078_0432_CCR_23_2250
crossref_primary_10_1038_s41598_020_65895_0
crossref_primary_10_3390_cancers13153865
crossref_primary_10_3390_cancers12071873
crossref_primary_10_3390_cancers15245760
crossref_primary_10_1002_jbt_23525
crossref_primary_10_2217_fon_2021_1549
crossref_primary_10_1007_s40846_023_00836_6
crossref_primary_10_1080_07357907_2022_2108827
crossref_primary_10_1186_s13045_019_0756_z
crossref_primary_10_1016_S1470_2045_19_30324_9
crossref_primary_10_2217_imt_2020_0301
crossref_primary_10_1016_j_ejca_2018_10_006
crossref_primary_10_3390_cancers16193266
crossref_primary_10_1245_s10434_022_12086_y
crossref_primary_10_1007_s11523_018_0583_0
crossref_primary_10_1016_j_bbcan_2024_189215
crossref_primary_10_3390_diagnostics15111377
crossref_primary_10_1136_jitc_2022_006624
crossref_primary_10_1002_iju5_12182
crossref_primary_10_1038_s41467_022_30496_0
crossref_primary_10_7759_cureus_59406
crossref_primary_10_1016_j_bbcan_2021_188606
crossref_primary_10_3390_diagnostics13193022
crossref_primary_10_3389_fimmu_2024_1391954
crossref_primary_10_1016_j_soc_2022_03_011
crossref_primary_10_1158_1078_0432_CCR_22_3911
crossref_primary_10_1016_j_soc_2022_03_013
crossref_primary_10_3390_ijms21051594
crossref_primary_10_1002_cam4_2661
crossref_primary_10_1093_qjmed_hcab014
crossref_primary_10_1080_14656566_2023_2224500
crossref_primary_10_2217_fon_2020_0118
crossref_primary_10_1016_j_jvir_2023_10_033
crossref_primary_10_3390_jcm13123620
crossref_primary_10_1158_1078_0432_CCR_23_0250
crossref_primary_10_3390_biomedicines9080935
crossref_primary_10_1007_s11864_021_00897_2
crossref_primary_10_1016_j_pharmthera_2018_02_014
crossref_primary_10_1016_j_soc_2022_03_004
crossref_primary_10_1007_s40944_024_00842_9
crossref_primary_10_1016_j_soc_2022_03_006
crossref_primary_10_1038_s41467_024_45306_y
crossref_primary_10_1080_2162402X_2018_1475873
crossref_primary_10_1186_s12885_021_07843_3
crossref_primary_10_1016_j_soc_2022_03_003
crossref_primary_10_3390_cancers17172780
crossref_primary_10_1186_s12957_020_01933_5
crossref_primary_10_3892_ol_2025_15189
crossref_primary_10_1007_s11523_025_01145_5
crossref_primary_10_3390_ijms22020493
crossref_primary_10_1080_14737140_2020_1753511
crossref_primary_10_2217_pme_2020_0006
crossref_primary_10_3389_fonc_2018_00435
crossref_primary_10_1007_s00262_019_02455_0
crossref_primary_10_1038_s41598_020_80216_1
crossref_primary_10_1093_oncolo_oyad052
crossref_primary_10_1186_s12967_021_02829_y
crossref_primary_10_3322_caac_21605
crossref_primary_10_1158_1078_0432_CCR_19_3335
crossref_primary_10_1016_j_jaccao_2024_01_002
crossref_primary_10_1111_pcmr_13139
crossref_primary_10_1186_s40425_019_0689_7
crossref_primary_10_1038_s41379_021_00882_y
crossref_primary_10_1097_CCO_0000000000000548
crossref_primary_10_2217_imt_2019_0120
crossref_primary_10_1136_jitc_2021_004149
crossref_primary_10_2147_CMAR_S351284
crossref_primary_10_1007_s40944_024_00855_4
crossref_primary_10_1158_1078_0432_CCR_23_1137
crossref_primary_10_1007_s00262_020_02552_5
crossref_primary_10_1016_j_ccell_2018_10_013
crossref_primary_10_1186_s40425_018_0421_z
crossref_primary_10_3389_fonc_2023_1150765
crossref_primary_10_1038_s43018_024_00743_y
crossref_primary_10_1016_j_omto_2021_12_007
crossref_primary_10_1093_ajcp_aqad003
crossref_primary_10_1155_2022_8901326
crossref_primary_10_4103_jcrt_jcrt_2269_23
crossref_primary_10_1136_bcr_2023_256697
crossref_primary_10_1007_s11864_023_01054_7
crossref_primary_10_1093_omcr_omz138
crossref_primary_10_1007_s00432_020_03390_9
crossref_primary_10_1186_s12957_022_02671_6
crossref_primary_10_3390_cells13010025
crossref_primary_10_1038_s42003_021_02683_0
crossref_primary_10_3390_cancers13040886
crossref_primary_10_1016_j_ejca_2025_115600
crossref_primary_10_3390_cancers15061643
crossref_primary_10_1038_s41416_023_02413_9
crossref_primary_10_3389_fonc_2022_877434
crossref_primary_10_1186_s13256_021_02997_x
crossref_primary_10_2217_fon_2022_0615
crossref_primary_10_1038_s41598_023_30412_6
crossref_primary_10_1097_CCO_0000000000000651
crossref_primary_10_3390_cancers15030906
crossref_primary_10_1016_S1470_2045_22_00392_8
crossref_primary_10_1007_s00262_020_02774_7
crossref_primary_10_3389_fimmu_2025_1493329
crossref_primary_10_3389_fonc_2021_650292
crossref_primary_10_3390_antib9020017
crossref_primary_10_1038_s41392_025_02173_3
crossref_primary_10_1016_S1470_2045_22_00500_9
crossref_primary_10_1038_s41598_019_50888_5
crossref_primary_10_3390_cancers11050677
crossref_primary_10_1007_s11864_018_0525_1
crossref_primary_10_1186_s12964_024_01711_w
crossref_primary_10_3389_fimmu_2022_832593
crossref_primary_10_3390_ijms23084125
crossref_primary_10_1080_14737140_2022_2065986
crossref_primary_10_1038_s41467_020_17175_8
crossref_primary_10_1177_15569845241228604
crossref_primary_10_1186_s13046_019_1259_z
crossref_primary_10_1002_cncr_31517
crossref_primary_10_1016_j_apsb_2023_10_005
crossref_primary_10_2217_fon_2019_0285
crossref_primary_10_1136_jitc_2024_010543
crossref_primary_10_1136_jitc_2019_000271
crossref_primary_10_2106_JBJS_21_00196
crossref_primary_10_3390_ijms25021266
crossref_primary_10_1097_MD_0000000000025262
crossref_primary_10_7759_cureus_15606
crossref_primary_10_3390_cancers13102359
crossref_primary_10_3390_ijms20010170
crossref_primary_10_1158_1078_0432_CCR_19_3416
crossref_primary_10_1007_s11864_021_00928_y
crossref_primary_10_1080_1750743X_2025_2485670
crossref_primary_10_1007_s11864_024_01269_2
crossref_primary_10_1186_s12885_023_10758_w
crossref_primary_10_2217_imt_2020_0155
crossref_primary_10_1016_j_ejso_2021_12_465
crossref_primary_10_3389_fimmu_2025_1567736
crossref_primary_10_1002_ijc_33382
crossref_primary_10_1002_jso_26745
crossref_primary_10_1111_his_14377
crossref_primary_10_1089_jayao_2019_0113
crossref_primary_10_1136_jitc_2024_009472
crossref_primary_10_1002_mco2_489
crossref_primary_10_4103_ijc_ijc_1010_21
crossref_primary_10_1002_onco_13728
crossref_primary_10_3389_fimmu_2022_866561
crossref_primary_10_1007_s12032_025_03039_y
crossref_primary_10_1016_j_ejca_2024_115196
crossref_primary_10_1007_s11864_023_01056_5
crossref_primary_10_3390_cancers12010221
crossref_primary_10_3389_fonc_2020_00258
crossref_primary_10_3390_cancers13092151
crossref_primary_10_1007_s11864_022_01036_1
crossref_primary_10_3390_cancers17132117
crossref_primary_10_1007_s12254_020_00598_w
crossref_primary_10_3389_fimmu_2022_1087991
crossref_primary_10_1007_s11864_022_00944_6
crossref_primary_10_1136_jitc_2020_001696
crossref_primary_10_3390_cancers14215473
crossref_primary_10_1136_jitc_2020_001458
crossref_primary_10_1245_s10434_022_12517_w
crossref_primary_10_3390_medicina60071085
crossref_primary_10_1016_j_gore_2025_101814
crossref_primary_10_1186_s13045_023_01486_6
crossref_primary_10_1186_s13045_024_01650_6
crossref_primary_10_1016_j_ejca_2021_06_027
crossref_primary_10_1007_s12032_018_1196_2
crossref_primary_10_1136_jitc_2020_001561
crossref_primary_10_1080_2162402X_2020_1747340
crossref_primary_10_1097_CCO_0000000000001149
crossref_primary_10_1007_s00104_021_01539_x
crossref_primary_10_1159_000529811
crossref_primary_10_1080_14737140_2023_2200169
crossref_primary_10_1186_s40164_019_0150_0
crossref_primary_10_1038_s41467_024_44875_2
crossref_primary_10_3390_cancers16234053
crossref_primary_10_1016_j_ctrv_2023_102625
crossref_primary_10_3390_cancers15225469
crossref_primary_10_1186_s12935_021_01824_z
crossref_primary_10_1158_1078_0432_CCR_23_2976
crossref_primary_10_3389_fonc_2023_1116937
crossref_primary_10_2217_fon_2022_0635
crossref_primary_10_3389_fonc_2024_1502945
crossref_primary_10_1002_jso_26306
crossref_primary_10_1158_1078_0432_CCR_24_1454
crossref_primary_10_3390_biomedicines9081048
crossref_primary_10_1186_s12957_023_03212_5
crossref_primary_10_1177_00368504251315075
crossref_primary_10_1186_s12967_021_02858_7
crossref_primary_10_3389_fonc_2022_800484
crossref_primary_10_1016_j_ejca_2021_03_022
crossref_primary_10_3389_fimmu_2023_1226445
crossref_primary_10_1097_CJI_0000000000000332
crossref_primary_10_1177_1758835920937612
crossref_primary_10_3390_ijms24032858
crossref_primary_10_1002_jso_27526
crossref_primary_10_1016_j_canlet_2022_215690
crossref_primary_10_1016_j_ejca_2023_113501
crossref_primary_10_1007_s00262_021_02935_2
crossref_primary_10_1136_jitc_2025_011517
crossref_primary_10_3390_cancers15061692
crossref_primary_10_1186_s40425_018_0413_z
crossref_primary_10_1136_jitc_2020_001772
crossref_primary_10_1186_s13018_022_03283_2
crossref_primary_10_1016_j_ctrv_2018_08_006
crossref_primary_10_1007_s00262_023_03387_6
crossref_primary_10_1002_cncr_35965
crossref_primary_10_1016_j_jbo_2019_100221
crossref_primary_10_1007_s00262_025_04007_1
crossref_primary_10_1016_j_ctrv_2024_102716
crossref_primary_10_1016_j_semcancer_2019_11_009
crossref_primary_10_1259_bjr_20220565
crossref_primary_10_1158_1078_0432_CCR_23_0742
crossref_primary_10_1158_1078_0432_CCR_25_0618
crossref_primary_10_3389_fimmu_2024_1448464
crossref_primary_10_1016_j_ejca_2021_04_034
crossref_primary_10_1158_1078_0432_CCR_23_0749
crossref_primary_10_1136_jitc_2020_000798
crossref_primary_10_3390_biomedicines10092146
crossref_primary_10_1177_10600280231187421
crossref_primary_10_3389_fphar_2020_00722
crossref_primary_10_3390_cancers12113321
crossref_primary_10_1016_j_intimp_2025_114070
crossref_primary_10_3389_fonc_2023_1124517
crossref_primary_10_1038_s41392_020_0205_z
crossref_primary_10_3389_fimmu_2024_1347404
crossref_primary_10_1016_j_jprot_2021_104236
crossref_primary_10_1016_j_currproblcancer_2019_06_001
crossref_primary_10_1158_1078_0432_CCR_23_0876
crossref_primary_10_1016_j_oraloncology_2021_105466
crossref_primary_10_3389_fimmu_2023_1190210
crossref_primary_10_1016_j_tips_2023_12_006
crossref_primary_10_1136_jitc_2020_000665
crossref_primary_10_1136_jitc_2020_000667
crossref_primary_10_1007_s11864_025_01307_7
crossref_primary_10_1016_S1470_2045_19_30153_6
crossref_primary_10_1158_1078_0432_CCR_22_2164
crossref_primary_10_1200_EDBK_321341
crossref_primary_10_1097_IOP_0000000000001240
crossref_primary_10_1186_s12885_025_13712_0
crossref_primary_10_1186_s12943_024_02105_9
crossref_primary_10_3892_ol_2024_14377
crossref_primary_10_1016_j_jdcr_2018_04_011
crossref_primary_10_3390_cancers15102735
crossref_primary_10_1080_02656736_2024_2430333
crossref_primary_10_3390_cancers13194816
crossref_primary_10_3390_cancers15082287
crossref_primary_10_3390_cancers13112796
crossref_primary_10_1080_2162402X_2020_1792036
crossref_primary_10_1007_s13402_020_00496_7
crossref_primary_10_1016_j_radonc_2023_109824
crossref_primary_10_1038_s41698_021_00150_x
crossref_primary_10_1177_10732748241237331
crossref_primary_10_1016_j_jaccao_2023_11_007
crossref_primary_10_1016_j_suronc_2024_102125
crossref_primary_10_1002_jso_27567
crossref_primary_10_1186_s12885_025_14007_0
crossref_primary_10_3389_fmolb_2021_747650
crossref_primary_10_1080_08923973_2021_1924195
crossref_primary_10_2217_imt_2022_0049
crossref_primary_10_1016_j_pharmthera_2018_09_008
crossref_primary_10_1016_j_currproblcancer_2019_06_004
Cites_doi 10.2307/2529712
10.1016/j.humpath.2014.11.001
10.1056/NEJMoa1414428
10.1016/S0140-6736(15)01283-0
10.1016/S0140-6736(16)00561-4
10.1093/annonc/mdu342.3
10.1155/2013/168145
10.1016/S1470-2045(16)30364-3
10.1080/01621459.1958.10501452
10.1016/S1470-2045(16)30624-6
10.1016/S1470-2045(17)30622-8
10.1002/cncr.30738
10.1016/S1470-2045(17)30624-1
10.1126/science.aaa1348
10.1016/S0140-6736(16)30587-6
10.1056/NEJMoa1003466
10.1056/NEJMoa1406498
10.1056/NEJMoa1302369
10.1016/0197-2456(89)90015-9
10.1016/S0140-6736(15)01281-7
10.1038/nrc3239
10.1016/S0140-6736(12)60651-5
10.1016/S1470-2045(15)70076-8
10.1038/nature13954
10.1200/JCO.2015.62.4734
10.1016/S1470-2045(17)30239-5
10.1002/cncr.30726
10.1016/S1470-2045(09)70334-1
10.1073/pnas.0915174107
ContentType Journal Article
Copyright 2018 Elsevier Ltd
Elsevier Ltd
Copyright © 2018 Elsevier Ltd. All rights reserved.
Copyright Elsevier Limited Mar 1, 2018
2018. Elsevier Ltd
Copyright_xml – notice: 2018 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2018 Elsevier Ltd. All rights reserved.
– notice: Copyright Elsevier Limited Mar 1, 2018
– notice: 2018. Elsevier Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TO
7X7
7XB
88E
8AO
8C1
8C2
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1016/S1470-2045(18)30006-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (ProQuest)
Lancet Titles
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
ProQuest Databases
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
Lancet Titles
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Oncogenes and Growth Factors Abstracts

Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7RV
  name: Nursing & Allied Health Database
  url: https://search.proquest.com/nahs
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1474-5488
EndPage 426
ExternalDocumentID 29370992
10_1016_S1470_2045_18_30006_8
S1470204518300068
1_s2_0_S1470204518300068
Genre Multicenter Study
Clinical Trial, Phase II
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation Alliance Clinical Trials in Oncology, National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, Cycle for Survival.
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: UG1 CA189858
– fundername: NCI NIH HHS
  grantid: U10 CA180821
– fundername: NCI NIH HHS
  grantid: U10 CA180882
– fundername: NCI NIH HHS
  grantid: U10 CA045808
– fundername: NCI NIH HHS
  grantid: U10 CA007968
– fundername: NCI NIH HHS
  grantid: U10 CA180791
– fundername: NCI NIH HHS
  grantid: U10 CA180833
– fundername: NCI NIH HHS
  grantid: P30 CA008748
– fundername: NCI NIH HHS
  grantid: P30 CA086862
– fundername: NCI NIH HHS
  grantid: U10 CA077440
GroupedDBID ---
--K
--M
-RU
.1-
.55
.FO
0R~
123
1B1
1P~
1~5
29L
4.4
457
4CK
4G.
53G
5VS
6PF
7-5
71M
7RV
7X7
88E
8AO
8C1
8C2
8FI
8FJ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAMRU
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABMAC
ABMZM
ABUWG
ABWVN
ACGFS
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFKRA
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AHMBA
AIGII
AIIUN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BENPR
BKEYQ
BKOJK
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
HMCUK
HVGLF
HZ~
IHE
J1W
KOM
M1P
M41
MO0
N9A
NAPCQ
O-L
O9-
OC~
OO-
OZT
P-8
P-9
P2P
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
R2-
ROL
RPZ
SDG
SEL
SES
SPCBC
SSH
SSZ
T5K
TLN
UKHRP
UV1
WOW
X7M
XBR
Z5R
~HD
3V.
AACTN
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
RIG
SDF
ABLVK
ABYKQ
AHPSJ
AJBFU
ZA5
9DU
AAYXX
AFFHD
CITATION
AGCQF
AGRNS
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c577t-4051b80d9e3130df1fccc16f81870c0b2e3e5e0d865c5ab23c5f05b85648c9373
IEDL.DBID BENPR
ISICitedReferencesCount 574
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000426466100056&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1470-2045
1474-5488
IngestDate Sun Nov 09 10:12:04 EST 2025
Tue Oct 07 05:35:36 EDT 2025
Tue Oct 07 05:18:27 EDT 2025
Mon Jul 21 06:00:59 EDT 2025
Sat Nov 29 07:00:44 EST 2025
Tue Nov 18 21:58:39 EST 2025
Fri Feb 23 02:43:41 EST 2024
Sun Feb 23 10:18:51 EST 2025
Tue Oct 14 19:35:42 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License Copyright © 2018 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c577t-4051b80d9e3130df1fccc16f81870c0b2e3e5e0d865c5ab23c5f05b85648c9373
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/6126546
PMID 29370992
PQID 2012358187
PQPubID 46089
PageCount 11
ParticipantIDs proquest_miscellaneous_1992016506
proquest_journals_2566236980
proquest_journals_2012358187
pubmed_primary_29370992
crossref_primary_10_1016_S1470_2045_18_30006_8
crossref_citationtrail_10_1016_S1470_2045_18_30006_8
elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30006_8
elsevier_clinicalkeyesjournals_1_s2_0_S1470204518300068
elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30006_8
PublicationCentury 2000
PublicationDate 2018-03-01
PublicationDateYYYYMMDD 2018-03-01
PublicationDate_xml – month: 03
  year: 2018
  text: 2018-03-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle The lancet oncology
PublicationTitleAlternate Lancet Oncol
PublicationYear 2018
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Maki, Jungbluth, Gnjatic (bib18) 2013; 2013
Demetri, von Mehren, Jones (bib3) 2016; 34
Snyder, Makarov, Merghoub (bib29) 2014; 371
Herbst, Baas, Kim (bib12) 2016; 387
Kaplan, Meier (bib25) 1958; 53
Heery, O'Sullivan-Coyne, Madan (bib11) 2017; 18
van der Graaf, Blay, Chawla (bib5) 2012; 379
Tumeh, Harview, Yearley (bib30) 2014; 515
Pocock, Simon (bib23) 1975; 31
Pardoll (bib14) 2012; 12
Weber, D'Angelo, Minor (bib9) 2015; 16
Postow, Chesney, Pavlick (bib27) 2015; 372
Siegel, Miller, Jemal (bib1) 2016; 66
Hammers, Plimack, Infante (bib7) 2014; 25
Hodi, O'Day, McDermott (bib13) 2010; 363
Kaufman, Russell, Hamid (bib17) 2016; 17
Schöffski, Chawla, Maki (bib4) 2016; 387
Tap, Jones, Van Tine (bib6) 2016; 388
Rosenberg, Hoffman-Censits, Powles (bib8) 2016; 387
Tawbi, Burgess, Bolejack (bib19) 2017; 18
Wolchok, Neyns, Linette (bib26) 2010; 11
Seddon, Strauss, Whelan (bib2) 2017; 18
Rizvi, Hellmann, Snyder (bib28) 2015; 348
Raj, Bui, Gonzales, Letson, Antonia (bib16) 2014; 25
Curran, Montalvo, Yagita, Allison (bib21) 2010; 107
D'Angelo, Shoushtari, Agaram (bib15) 2015; 46
Wolchok, Kluger, Callahan (bib10) 2013; 369
Ben-Ami, Barysauskas, Solomon (bib31) 2017; 123
Hellmann, Rizvi, Goldman (bib22) 2017; 18
Pollack, He, Yearley (bib20) 2017; 123
Wolchok (10.1016/S1470-2045(18)30006-8_bib10) 2013; 369
Hammers (10.1016/S1470-2045(18)30006-8_bib7) 2014; 25
Raj (10.1016/S1470-2045(18)30006-8_bib16) 2014; 25
Hellmann (10.1016/S1470-2045(18)30006-8_bib22) 2017; 18
Pocock (10.1016/S1470-2045(18)30006-8_bib23) 1975; 31
Pardoll (10.1016/S1470-2045(18)30006-8_bib14) 2012; 12
Schöffski (10.1016/S1470-2045(18)30006-8_bib4) 2016; 387
D'Angelo (10.1016/S1470-2045(18)30006-8_bib15) 2015; 46
Tumeh (10.1016/S1470-2045(18)30006-8_bib30) 2014; 515
Maki (10.1016/S1470-2045(18)30006-8_bib18) 2013; 2013
Tawbi (10.1016/S1470-2045(18)30006-8_bib19) 2017; 18
Simon (10.1016/S1470-2045(18)30006-8_bib24) 1989; 10
Rosenberg (10.1016/S1470-2045(18)30006-8_bib8) 2016; 387
Heery (10.1016/S1470-2045(18)30006-8_bib11) 2017; 18
Demetri (10.1016/S1470-2045(18)30006-8_bib3) 2016; 34
Seddon (10.1016/S1470-2045(18)30006-8_bib2) 2017; 18
Herbst (10.1016/S1470-2045(18)30006-8_bib12) 2016; 387
Curran (10.1016/S1470-2045(18)30006-8_bib21) 2010; 107
Rizvi (10.1016/S1470-2045(18)30006-8_bib28) 2015; 348
Weber (10.1016/S1470-2045(18)30006-8_bib9) 2015; 16
Postow (10.1016/S1470-2045(18)30006-8_bib27) 2015; 372
Kaufman (10.1016/S1470-2045(18)30006-8_bib17) 2016; 17
Kaplan (10.1016/S1470-2045(18)30006-8_bib25) 1958; 53
Wolchok (10.1016/S1470-2045(18)30006-8_bib26) 2010; 11
Ben-Ami (10.1016/S1470-2045(18)30006-8_bib31) 2017; 123
Siegel (10.1016/S1470-2045(18)30006-8_bib1) 2016; 66
Pollack (10.1016/S1470-2045(18)30006-8_bib20) 2017; 123
Snyder (10.1016/S1470-2045(18)30006-8_bib29) 2014; 371
Tap (10.1016/S1470-2045(18)30006-8_bib6) 2016; 388
van der Graaf (10.1016/S1470-2045(18)30006-8_bib5) 2012; 379
Hodi (10.1016/S1470-2045(18)30006-8_bib13) 2010; 363
29370991 - Lancet Oncol. 2018 Mar;19(3):283-285
References_xml – volume: 388
  start-page: 488
  year: 2016
  end-page: 497
  ident: bib6
  article-title: Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
  publication-title: Lancet
– volume: 34
  start-page: 786
  year: 2016
  end-page: 793
  ident: bib3
  article-title: Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial
  publication-title: J Clin Oncol
– volume: 369
  start-page: 122
  year: 2013
  end-page: 133
  ident: bib10
  article-title: Nivolumab plus ipilimumab in advanced melanoma
  publication-title: N Engl J Med
– volume: 46
  start-page: 357
  year: 2015
  end-page: 365
  ident: bib15
  article-title: Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
  publication-title: Hum Pathol
– volume: 25
  year: 2014
  ident: bib16
  article-title: Impact of PD-L1 expression on clinical outcomes in subtypes of sarcoma
  publication-title: Ann Oncol
– volume: 123
  start-page: 3285
  year: 2017
  end-page: 3290
  ident: bib31
  article-title: Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study
  publication-title: Cancer
– volume: 53
  start-page: 457
  year: 1958
  end-page: 481
  ident: bib25
  article-title: Nonparametric-estimation from incomplete observations
  publication-title: J Am Stat Assoc
– volume: 387
  start-page: 1540
  year: 2016
  end-page: 1550
  ident: bib12
  article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
  publication-title: Lancet
– volume: 18
  start-page: 1397
  year: 2017
  end-page: 1410
  ident: bib2
  article-title: Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
  publication-title: Lancet Oncol
– volume: 107
  start-page: 4275
  year: 2010
  end-page: 4280
  ident: bib21
  article-title: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
  publication-title: Proc Natl Acad Sci U S A
– volume: 348
  start-page: 124
  year: 2015
  end-page: 128
  ident: bib28
  article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
  publication-title: Science
– volume: 18
  start-page: 1493
  year: 2017
  end-page: 1501
  ident: bib19
  article-title: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
  publication-title: Lancet Oncol
– volume: 123
  start-page: 3291
  year: 2017
  end-page: 3304
  ident: bib20
  article-title: T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas
  publication-title: Cancer
– volume: 387
  start-page: 1629
  year: 2016
  end-page: 1637
  ident: bib4
  article-title: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
  publication-title: Lancet
– volume: 11
  start-page: 155
  year: 2010
  end-page: 164
  ident: bib26
  article-title: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
  publication-title: Lancet Oncol
– volume: 31
  start-page: 103
  year: 1975
  end-page: 115
  ident: bib23
  article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
  publication-title: Biometrics
– volume: 363
  start-page: 711
  year: 2010
  end-page: 723
  ident: bib13
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: N Engl J Med
– volume: 372
  start-page: 2006
  year: 2015
  end-page: 2017
  ident: bib27
  article-title: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
  publication-title: N Engl J Med
– volume: 12
  start-page: 252
  year: 2012
  end-page: 264
  ident: bib14
  article-title: The blockade of immune checkpoints in cancer immunotherapy
  publication-title: Nat Rev Cancer
– volume: 2013
  start-page: 168145
  year: 2013
  ident: bib18
  article-title: A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma
  publication-title: Sarcoma
– volume: 387
  start-page: 1909
  year: 2016
  end-page: 1920
  ident: bib8
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
– volume: 371
  start-page: 2189
  year: 2014
  end-page: 2199
  ident: bib29
  article-title: Genetic basis for clinical response to CTLA-4 blockade in melanoma
  publication-title: N Engl J Med
– volume: 66
  start-page: 7
  year: 2016
  end-page: 30
  ident: bib1
  article-title: Cancer statistics, 2016
  publication-title: CA Cancer J Clin
– volume: 379
  start-page: 1879
  year: 2012
  end-page: 1886
  ident: bib5
  article-title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
  publication-title: Lancet
– volume: 16
  start-page: 375
  year: 2015
  end-page: 384
  ident: bib9
  article-title: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
  publication-title: Lancet Oncol
– volume: 18
  start-page: 31
  year: 2017
  end-page: 41
  ident: bib22
  article-title: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
  publication-title: Lancet Oncol
– volume: 25
  start-page: iv361
  year: 2014
  end-page: iv362
  ident: bib7
  article-title: Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma
  publication-title: Ann Oncol
– volume: 18
  start-page: 587
  year: 2017
  end-page: 598
  ident: bib11
  article-title: Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
  publication-title: Lancet Oncol
– volume: 17
  start-page: 1374
  year: 2016
  end-page: 1385
  ident: bib17
  article-title: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
  publication-title: Lancet Oncol
– volume: 515
  start-page: 568
  year: 2014
  end-page: 571
  ident: bib30
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
– volume: 31
  start-page: 103
  year: 1975
  ident: 10.1016/S1470-2045(18)30006-8_bib23
  article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
  publication-title: Biometrics
  doi: 10.2307/2529712
– volume: 46
  start-page: 357
  year: 2015
  ident: 10.1016/S1470-2045(18)30006-8_bib15
  article-title: Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2014.11.001
– volume: 372
  start-page: 2006
  year: 2015
  ident: 10.1016/S1470-2045(18)30006-8_bib27
  article-title: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1414428
– volume: 387
  start-page: 1629
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib4
  article-title: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)01283-0
– volume: 387
  start-page: 1909
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib8
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00561-4
– volume: 25
  start-page: iv361
  issue: suppl
  year: 2014
  ident: 10.1016/S1470-2045(18)30006-8_bib7
  article-title: Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu342.3
– volume: 2013
  start-page: 168145
  year: 2013
  ident: 10.1016/S1470-2045(18)30006-8_bib18
  article-title: A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma
  publication-title: Sarcoma
  doi: 10.1155/2013/168145
– volume: 17
  start-page: 1374
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib17
  article-title: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30364-3
– volume: 53
  start-page: 457
  year: 1958
  ident: 10.1016/S1470-2045(18)30006-8_bib25
  article-title: Nonparametric-estimation from incomplete observations
  publication-title: J Am Stat Assoc
  doi: 10.1080/01621459.1958.10501452
– volume: 25
  issue: suppl 4
  year: 2014
  ident: 10.1016/S1470-2045(18)30006-8_bib16
  article-title: Impact of PD-L1 expression on clinical outcomes in subtypes of sarcoma
  publication-title: Ann Oncol
– volume: 18
  start-page: 31
  year: 2017
  ident: 10.1016/S1470-2045(18)30006-8_bib22
  article-title: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)30624-6
– volume: 18
  start-page: 1397
  year: 2017
  ident: 10.1016/S1470-2045(18)30006-8_bib2
  article-title: Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30622-8
– volume: 123
  start-page: 3285
  year: 2017
  ident: 10.1016/S1470-2045(18)30006-8_bib31
  article-title: Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study
  publication-title: Cancer
  doi: 10.1002/cncr.30738
– volume: 18
  start-page: 1493
  year: 2017
  ident: 10.1016/S1470-2045(18)30006-8_bib19
  article-title: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30624-1
– volume: 348
  start-page: 124
  year: 2015
  ident: 10.1016/S1470-2045(18)30006-8_bib28
  article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
  publication-title: Science
  doi: 10.1126/science.aaa1348
– volume: 66
  start-page: 7
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib1
  article-title: Cancer statistics, 2016
  publication-title: CA Cancer J Clin
– volume: 388
  start-page: 488
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib6
  article-title: Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30587-6
– volume: 363
  start-page: 711
  year: 2010
  ident: 10.1016/S1470-2045(18)30006-8_bib13
  article-title: Improved survival with ipilimumab in patients with metastatic melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1003466
– volume: 371
  start-page: 2189
  year: 2014
  ident: 10.1016/S1470-2045(18)30006-8_bib29
  article-title: Genetic basis for clinical response to CTLA-4 blockade in melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1406498
– volume: 369
  start-page: 122
  year: 2013
  ident: 10.1016/S1470-2045(18)30006-8_bib10
  article-title: Nivolumab plus ipilimumab in advanced melanoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1302369
– volume: 10
  start-page: 1
  year: 1989
  ident: 10.1016/S1470-2045(18)30006-8_bib24
  article-title: Optimal two-stage designs for phase II clinical trials
  publication-title: Control Clin Trials
  doi: 10.1016/0197-2456(89)90015-9
– volume: 387
  start-page: 1540
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib12
  article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)01281-7
– volume: 12
  start-page: 252
  year: 2012
  ident: 10.1016/S1470-2045(18)30006-8_bib14
  article-title: The blockade of immune checkpoints in cancer immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3239
– volume: 379
  start-page: 1879
  year: 2012
  ident: 10.1016/S1470-2045(18)30006-8_bib5
  article-title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)60651-5
– volume: 16
  start-page: 375
  year: 2015
  ident: 10.1016/S1470-2045(18)30006-8_bib9
  article-title: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)70076-8
– volume: 515
  start-page: 568
  year: 2014
  ident: 10.1016/S1470-2045(18)30006-8_bib30
  article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance
  publication-title: Nature
  doi: 10.1038/nature13954
– volume: 34
  start-page: 786
  year: 2016
  ident: 10.1016/S1470-2045(18)30006-8_bib3
  article-title: Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.62.4734
– volume: 18
  start-page: 587
  year: 2017
  ident: 10.1016/S1470-2045(18)30006-8_bib11
  article-title: Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30239-5
– volume: 123
  start-page: 3291
  year: 2017
  ident: 10.1016/S1470-2045(18)30006-8_bib20
  article-title: T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas
  publication-title: Cancer
  doi: 10.1002/cncr.30726
– volume: 11
  start-page: 155
  year: 2010
  ident: 10.1016/S1470-2045(18)30006-8_bib26
  article-title: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70334-1
– volume: 107
  start-page: 4275
  year: 2010
  ident: 10.1016/S1470-2045(18)30006-8_bib21
  article-title: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0915174107
– reference: 29370991 - Lancet Oncol. 2018 Mar;19(3):283-285
SSID ssj0017105
Score 2.6899407
Snippet Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4, respectively. We...
SummaryBackgroundPatients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and CTLA-4,...
Sarcomas are rare, heterogeneous malignant tumours of mesenchymal origin characterised into more than 100 distinct subtypes, accounting for 1% of malignancies...
Summary Background Patients with metastatic sarcoma have limited treatment options. Nivolumab and ipilimumab are monoclonal antibodies targeting PD-1 and...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 416
SubjectTerms Adult
Adverse events
Aged
Aged, 80 and over
Alanine
Alanine transaminase
Anemia
Anorexia
Antibodies
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Aspartate aminotransferase
Biomarkers
Bone cancer
Cancer therapies
Cell number
Chemotherapy
Clinical trials
Creatinine
CTLA-4 protein
Dehydration
Diarrhea
Disease
FDA approval
Female
Fever
Hematology, Oncology, and Palliative Medicine
Humans
Hypotension
Immunotherapy
Intravenous administration
Ipilimumab - adverse effects
Ipilimumab - therapeutic use
Ligands
Liposarcoma
Lung cancer
Lymphocytes
Male
Medical prognosis
Melanoma
Metastases
Metastasis
Middle Aged
Monoclonal antibodies
Neoplasia
Nivolumab - adverse effects
Nivolumab - therapeutic use
Oncology
Pain
Patients
PD-1 protein
Pleural effusion
Pruritus
Respiratory failure
Sarcoma
Sarcoma - drug therapy
Sarcoma - immunology
Sarcoma - mortality
Sarcoma - secondary
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - immunology
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - pathology
Soft tissue sarcoma
Solid tumors
Targeted cancer therapy
Time Factors
Treatment Outcome
Tumors
United States
Urinary tract
Young Adult
Title Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518300068
https://www.clinicalkey.es/playcontent/1-s2.0-S1470204518300068
https://dx.doi.org/10.1016/S1470-2045(18)30006-8
https://www.ncbi.nlm.nih.gov/pubmed/29370992
https://www.proquest.com/docview/2012358187
https://www.proquest.com/docview/2566236980
https://www.proquest.com/docview/1992016506
Volume 19
WOSCitedRecordID wos000426466100056&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251014
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7X7
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251014
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7RV
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251014
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: BENPR
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database (ProQuest)
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20251014
  omitProxy: false
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 8C1
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoixAX3tCFUhmJQyttIHbi2OGClqoVB1hV5aG9WYnjiEi7m-0mC7-E_8uM42QvLUXi4ihrjezsvD4_ZoaQ16ksAXcULMg5ljATEeicTUxQMpWnWZSy2LqU-Z_kdKpms_Tcb7g1_lplbxOdoS5qg3vksEh3UZ1MyferywCrRuHpqi-hsUP2MFMZyPneh9Pp-cVwjiC7S4wslmGAide3MTxvvww_HjF1HKHdDtR13uk69Om80Nn9_53_A3LP40866QTmIblll4_Inc_-hP0x-T2tnMHKcopbtLReu2e9aWm1qubVwnUN19MpYF66sG2GgUmVoQ3oTb3I6NEEt3FAoOgEoAKsro7f0fZXTbFYVwCCZ-djuqyXgdkmHx9TcJtFDXJnizFd_QD3Sjl1VUWaJ-Tb2enXk4-BL90QGCFlC6tSwXIVFqmNwEkWJSuNMSwp8ftDE-bcRlbYsFCJMCLLeWREGYpciSRWBhBT9JTswizsPqGKlyoBGBqX0sQAPzJWxDme5gIFBtONSNyzTBuf1xzLa8z1cIENOa2R05op7Tit1Yi8GchWXWKPmwiSXh50H7UKdlaD67mJUF5FaBtvLRrNdMN12FEjMZhZJAVKNVB6QNQBnX8Z9KAXQz2Ms5XBq7sB2vMoSVU4Iq-GbmA7niFlS1tvYKppyjECLkxG5FmnCcPfB8hRguLz538f-wW5Cy-qu8h3QHbb9ca-JLfNz7Zq1odkR158x3YmXaugVSfs0Gv2H7vnSNQ
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwEB6VgoAX7mOhgJFAaqUNxM5hBwmhFVC1artCUFDfTOI4ItLuZtlkqfgh_A1-IzO59qWlvPSBp0ixJk6cOb6x5wB4FskMcUfKnURQC7PAQ5mzoXEyrpIo9iLu27pk_r4cj9XRUfRhDX53uTAUVtnpxFpRp4WhPXJ00uusTq7km_l3h7pG0elq10KjYYs9-_MYXbby9e47_L_Phdh-f_h2x2m7CjgmkLJChyngiXLTyHqov9OMZ8YYHmb0aNe4ibCeDaybqjAwQZwIzwSZGyQqCH1l0Jh7-NwLcBH1OKdWEfLjl_7UQjYhk9yXrkNl3lcZQy8_9Tc3udryyEo46jRbeBrWrW3e9vX_bbVuwLUWXbNRIw43Yc3ObsHlgzZ-4Db8Gue1Oo4TRhvQrFjU12JZsXyeT_JpPdQH3zNE9Gxqq5jSrnLDSvygYhqzzRFtUqG4sBECIfQdt16x6rhg1IrMQbGykyGbFTPHrEqrDxmCgrRAqbLpkM2_IXhggtU9U8o78PlcFuUurONb2PvAlMhUiCDbz6TxEVzFPPUTOqtGCkoVHIDfsYg2bdV2ah4y0X14HnGWJs7SXOmas7QawIuebN6ULTmLIOz4T3c5uWhFNBrWswjlSYS2bHVhqbkuhXYbaiJGI0KkSKl6yhbuNTDuXybd6Nhe9_OseP7kYXRchBdGyh3A034YfzudkMUzWyzxVaNIUH6fGw7gXiN5_fIhLpao1sSDv8_9BK7sHB7s6_3d8d5DuIoDqglZ3ID1arG0j-CS-VHl5eJxrTsYfD1v8fsDxPOgBA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKi6peKFthoICRQGqlCY2dxQ4SQgPtiKolGrFIvbmJ46iRZibDJEPVH8Kf4dfxXra5tJRLD5wixXpx4rzle_ZbCHkViBRwR8KsmGMLM88BmTO-tlIm4yByAuaaqmT-sQhDeXISjFbI7zYXBsMqW51YKeok17hHDk56ldXJpNhLm7CI0f7w_eyHhR2k8KS1badRs8iRuTgH9614d7gP__o158ODbx8_WU2HAUt7QpTgPHkslnYSGAd0eZKyVGvN_BSnsbUdc-MYz9iJ9D3tRTF3tJfaXiw935UaDLsDz71F1gR8Ezh-ax8OwtGX7gxD1AGUzBW2hUXfl_lDe1-7mztM7jpoMyx5lWW8CvlWFnC4-T-v3V1yp8HddFALyj2yYqb3yfrnJrLgAfkVZpWijmKKW9M0n1fXfFHSbJaNs0k11IXlU8D6dGLKCBOyMk0L-KB8EtGdAW5fgSDRAUAk8Cp339LyPKfYpMwCgTPjPp3mU0svi673KcCFJAd5M0mfzs4AVlBOq24qxUPy_UYWZYuswluYx4RKnkof4LebCu0C7IpY4sZ4ig0UmETYI27LLko39dyxrchYdYF7yGUKuUwxqSouU7JH3nRks7qgyXUEfsuLqs3WBfuiwOReRyguIzRFoyULxVTBlV1TIzGYFyQFStlRNkCwBnj_Mul2KwKqm2fJ_5cPg0vDHT-Qdo-87Ibht-PZWTQ1-QJeNQg4Zv7Zfo88qqWwWz5AzAIUHn_y97lfkHWQOnV8GB49JRtwX9axjNtktZwvzDNyW_8ss2L-vFEklJzetPz9AaZ0qgE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nivolumab+with+or+without+ipilimumab+treatment+for+metastatic+sarcoma+%28Alliance+A091401%29%3A+two+open-label%2C+non-comparative%2C+randomised%2C+phase+2+trials&rft.jtitle=The+lancet+oncology&rft.au=D%27Angelo%2C+Sandra+P&rft.au=Mahoney%2C+Michelle+R&rft.au=Van+Tine%2C+Brian+A&rft.au=Atkins%2C+James&rft.date=2018-03-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.eissn=1474-5488&rft.volume=19&rft.issue=3&rft.spage=416&rft.epage=426&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930006-8&rft.externalDocID=S1470204518300068
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204518X00035%2Fcov150h.gif